



US 20140012133A1

(19) **United States**

(12) **Patent Application Publication**  
**Sverdlik et al.**

(10) **Pub. No.: US 2014/0012133 A1**  
(43) **Pub. Date: Jan. 9, 2014**

(54) **METHOD AND/OR APPARATUS FOR MEASURING RENAL DENERVATION EFFECTIVENESS**

*A61B 8/12* (2006.01)  
*A61B 8/06* (2006.01)  
*A61B 5/0476* (2006.01)  
*A61B 5/02* (2006.01)  
*A61B 8/04* (2006.01)

(71) Applicant: **CardioSonic Ltd.**, Tel-Aviv (IL)

(72) Inventors: **Ariel Sverdlik**, Tel-Aviv (IL); **Benny Dilmoney**, Givat Shmuel (IL); **Yehuda Zadok**, Holon (IL); **Or Shabtay**, Kibbutz Farod (IL)

(52) **U.S. Cl.**  
CPC ..... *A61B 5/4848* (2013.01); *A61B 5/02007* (2013.01); *A61B 5/026* (2013.01); *A61B 5/1076* (2013.01); *A61B 5/0205* (2013.01); *A61B 5/4836* (2013.01); *A61B 8/04* (2013.01); *A61N 7/022* (2013.01); *A61B 8/12* (2013.01); *A61B 8/06* (2013.01); *A61B 5/0476* (2013.01); *A61B 5/04005* (2013.01)  
USPC ..... **600/438**; 600/481; 600/505; 600/486; 600/587; 600/483; 600/439; 600/500

(21) Appl. No.: **13/905,224**

(22) Filed: **May 30, 2013**

**Related U.S. Application Data**


(60) Provisional application No. 61/653,515, filed on May 31, 2012.

**Publication Classification**

(51) **Int. Cl.**  
*A61B 5/00* (2006.01)  
*A61B 5/026* (2006.01)  
*A61B 5/107* (2006.01)  
*A61B 5/0205* (2006.01)  
*A61B 5/04* (2006.01)  
*A61N 7/02* (2006.01)

(57) **ABSTRACT**

The present invention, in some embodiments thereof, relates to methods and/or apparatus for measuring the effectiveness of a renal denervation treatment. In some embodiments, a method for determining effectiveness of the denervation treatment comprises tracking at least one of arterial wall movement, arterial blood flow rate, arterial blood flow velocity, blood pressure and arterial diameter at one or more selected locations in the renal artery over time, and assessing the effectiveness of said renal denervation treatment according to results obtained by tracking.






FIG.1




FIG. 2




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9

## METHOD AND/OR APPARATUS FOR MEASURING RENAL DENERVATION EFFECTIVENESS

### RELATED APPLICATION

[0001] This application claims the benefit of priority under 35 USC §119(e) of U.S. Provisional Patent Application No. 61/653,515 filed May 31, 2012, the contents of which are incorporated herein by reference in their entirety.

### FIELD AND BACKGROUND OF THE INVENTION

[0002] The present invention, in some embodiments thereof, relates to methods and/or apparatuses for measuring the effectiveness of a renal denervation treatment. A renal denervation is a procedure aimed at treating refractory hypertension, also considered as uncontrollable high blood pressure. Renal denervation uses ablation to reduce the activity of renal artery nerves. By reducing the sympathetic neural activity, blood pressure may be reduced.

[0003] European publication number 2594193 to Fain et al. discloses: "A renal denervation feedback method is described that performs a baseline measurement of renal nerve plexus electrical activity at a renal vessel; denervates at least some tissue proximate the renal vessel after performing the baseline measurement; performs a post-denervation measurement of renal nerve plexus electrical activity at the renal vessel, after the denervating; and assesses denervation of the renal vessel based on a comparison of the baseline measurement and the post-denervation measurement of renal nerve plexus electrical activity at the renal vessel."

### SUMMARY OF THE INVENTION

[0004] According to an aspect of some embodiments of the invention, there is provided a method for assessing renal denervation treatment, comprising inserting a measurement device into an artery, tracking at least one of arterial wall movement, arterial blood flow rate, arterial blood flow velocity, blood pressure and arterial diameter at one or more selected locations in the renal artery over time, and assessing the effectiveness of the renal denervation treatment according to results obtained by the tracking. In some embodiments, the selected location is a location of tissue ablation. In some embodiments, the selected location is at a distance of at least 0.5 cm from a location of tissue ablation. In some embodiments, tracking over time comprises measuring at least one of the parameters continuously during the denervation treatment. In some embodiments, tracking over time comprises measuring at least one of the parameters periodically every 30 seconds. In some embodiments, assessing is performed by analyzing measurement results of two or more parameters combined together. In some embodiments, assessing comprises detecting a change in arterial diameter over time. In some embodiments, a stiffness of the artery is determined according to an arterial wall movement profile measured over time. In some embodiments, effectiveness is assessed by comparing pre-denervation and post-denervation measurements. In some embodiments, a single measurement device adapted for emitting and receiving ultrasonic energy is used for treating and for measuring. In some embodiments, the measurement device is positioned externally to the renal artery. In some embodiments, a denervation treatment profile is adjusted according to results of the tracking of at least one

parameter. In some embodiments, assessing comprises determining if the denervation treatment should be repeated by applying a threshold to the at least one tracked parameter. Optionally, adjusting the denervation treatment profile comprises selecting at least one of a treatment duration, a treatment location, and an intensity of the applied energy for denervating the nerves.

[0005] According to an aspect of some embodiments of the invention, there is provided a device comprising a plurality of ultrasonic transceivers for determining effectiveness of a renal denervation treatment, wherein the device is adapted to measure renal artery stiffness using ultrasonic imaging. In some embodiments, the device is adapted to measure renal artery wall movement using echo signals reflected by the artery wall. In some embodiments, the device is adapted to calculate an amplitude of the artery wall movement by measuring a distance between at least one of the transceivers and the artery wall. In some embodiments, the device is adapted to measure a diameter of the renal artery using ultrasonic imaging. In some embodiments, the device is adapted to measure renal artery stiffness by calculating pulse wave velocity.

[0006] Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.

[0007] Implementation of the method and/or system of embodiments of the invention can involve performing or completing selected tasks manually, automatically, or a combination thereof. Moreover, according to actual instrumentation and equipment of embodiments of the method and/or system of the invention, several selected tasks could be implemented by hardware, by software or by firmware or by a combination thereof using an operating system.

[0008] For example, hardware for performing selected tasks according to embodiments of the invention could be implemented as a chip or a circuit. As software, selected tasks according to embodiments of the invention could be implemented as a plurality of software instructions being executed by a computer using any suitable operating system. In an exemplary embodiment of the invention, one or more tasks according to exemplary embodiments of method and/or system as described herein are performed by a data processor, such as a computing platform for executing a plurality of instructions. Optionally, the data processor includes a volatile memory for storing instructions and/or data and/or a non-volatile storage, for example, a magnetic hard-disk and/or removable media, for storing instructions and/or data. Optionally, a network connection is provided as well. A display and/or a user input device such as a keyboard or mouse are optionally provided as well.

### BRIEF DESCRIPTION OF THE DRAWINGS

[0009] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0010] Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.

[0011] In the drawings:

[0012] FIG. 1 is a schematic illustration of a method for measuring a magnetic field induced by neural activity, according to some embodiment of the invention;

[0013] FIG. 2 is a flowchart of a method for evaluating and/or measuring renal denervation by detecting current source density of renal neural signals using ultrasound current source density imaging (UCSDI), according to some embodiments of the invention;

[0014] FIGS. 3A-C are schematic illustrations and a flowchart of methods that include initiating an electric impulse to the artery wall, according to some embodiments of the invention;

[0015] FIG. 4 is a schematic illustration of a method which includes recording evoked potentials before and/or after denervation treatment, according to some embodiments of the invention;

[0016] FIG. 5 relates to a method for measuring and/or evaluating renal denervation based on optogenetic controls of neural excitability, according to some embodiments of the invention;

[0017] FIG. 6 is a flowchart of a general method for denervation treatment and assessment, according to some embodiments of the invention;

[0018] FIG. 7 is a flowchart of a method for assessing denervation treatment by tracking physiological changes at a specific location in the artery over time, according to some embodiments of the invention;

[0019] FIG. 8 is a drawing of a flow wire inserted into a renal artery, according to an exemplary method for evaluating mechanical parameters of the artery for assessing renal denervation; and

[0020] FIG. 9 is a drawing of a duplex ultrasound device positioned externally to a renal artery, according to an exemplary method for evaluating mechanical parameters of the artery for assessing renal denervation.

#### DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION

[0021] The present invention, in some embodiments thereof, relates to methods and/or apparatuses for measuring the effectiveness of a renal denervation treatment.

[0022] A broad aspect of some embodiments of the invention relates to obtaining feedback following a renal denervation treatment by measuring physiological parameters of the blood vessel and/or parameters relating to blood flow and/or parameters relating to neural activity and/or measuring a response to stimulation.

[0023] An aspect of some embodiments relates to measuring physiological changes over time at one or more selected locations along the renal artery. In some embodiments, the method comprises measuring physiological changes related to mechanical properties of the artery, such as blood flow rate, blood pressure, blood flow velocity, arterial diameter and/or artery wall movement. In some embodiments, measurements are performed at a tissue ablation location. Additionally and/

or alternatively, measurements are performed at a location in some distance from the tissue ablation location, for example at a distance of 2 cm, 0.5 cm, 4 cm or intermediate, larger or smaller distances from the denervation location, for example in vertical and/or horizontal directions in the artery.

[0024] In some embodiments, measurements are performed before and/or during and/or after denervation treatment. In some embodiments, measurements are performed periodically during the treatment, for example every second, every 2 minutes, every 15 minutes, or intermediate, shorter or longer time intervals. Optionally, the intervals are fixed intervals. Alternatively, the intervals vary, for example the intervals may be adjusted according to parameters such as the treatment duration at each of the locations in the artery. Optionally, measurements are performed continuously. In some embodiments, the duration of the treatment is, for example, between 0.5-4 hours, and measurements are performed at specific time points during the treatment.

[0025] In some embodiments, an arterial wall movement pattern is detected. In some embodiments, a narrowing and/or widening of the renal artery is detected. Optionally, arterial stiffness is assessed. Optionally, potential kidney functioning is assessed. In some embodiments, kidney function is determined according to arterial stiffness.

[0026] In some embodiments, a pattern may include a repetitive behavior, trend, and/or any other detected behavior of, for example, arterial diameter, arterial wall movement, blood pressure, and/or any other parameters described herein. Optionally, the pattern is detected over time. In one example, an arterial diameter pattern may include a repetitive behavior, for example narrowing and widening of the artery diameter in fixed time intervals, which may be linked to and/or indicate pulsation.

[0027] In some embodiments, the measured data is analyzed to deduce the effectiveness of the denervation treatment. In some embodiments, a threshold may be applied to determine if the treatment profile should be adjusted and/or to determine if the treatment should be repeated. In some embodiments, the results of at least two measured parameters, for example arterial diameter and blood flow velocity, are combined to deduce effectiveness.

[0028] Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details of construction and the arrangement of the components and/or methods set forth in the following description and/or illustrated in the drawings and/or the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.

[0029] Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.

[0030] An Exemplary Method for Measuring a Magnetic Field Induced by Neural Activity

[0031] Referring now to the drawings, FIG. 1 describes a method for measuring the magnetic field 101 inside a blood vessel lumen, according to some embodiment of the invention. Optionally, the magnetic field reflects a total magnetic field induced by current in the nerves 103 surrounding the blood vessel. In some embodiments, a SQUID magnetometer 105 comprising one or more coils is used for measuring the

magnetic field. Optionally, a plurality of coils are arranged in a parallel and/or serial manner and/or combination of them. Optionally, neural activity is stimulated, for example using an electrode within the artery, to initiate current in the nerves, and a SQUID magnetometer or any other magnetic field detecting device is used for measuring the magnetic field induced by the current conducted through the nerves. Optionally, a magnetic field within a lumen of the artery and/or a magnetic field externally to the artery is measured. Optionally, a stimulating device such as an electrode is positioned outside the artery. Optionally, a sensor for detecting the magnetic field is positioned outside the artery.

**[0032]** An Exemplary Method for Evaluating and/or Measuring Renal Denervation by Detecting Current Source Density of Renal Neural Signals Using Ultrasound Current Source Density Imaging (UCSDI)

**[0033]** FIG. 2 is a flowchart of a method for evaluating and/or measuring renal denervation by detecting current source density of renal neural signals using ultrasound current source density imaging (UCSDI), according to some embodiments of the invention. In some embodiments, the current source density is detected, for example distally to the denervation location, before (201) and/or after a renal denervation procedure (203). The technique is a direct 3-D imaging technique that potentially facilitates existing mapping procedures with superior spatial resolution. The technique is based on a pressure induced change in resistivity—acousto-electric (AE) effect, which is spatially confined to the ultrasound focus. Optionally, AE modulated voltage recordings are used to map and reconstruct the current densities. In some embodiments, a device such as a catheter comprising one or more ultrasonic transceivers and/or transducers is inserted into the renal artery. Optionally, ultrasonic energy is emitted by the device, and returning echo signals are received and/or recorded for further analysis.

**[0034]** Exemplary methods for denervation assessment which include initiation of an electric impulse to the artery wall FIGS. 3A-C relate to methods that include initiating an electric impulse to the artery wall, according to some embodiments of the invention. The following procedures may be performed:

**[0035]** 1. Initiate an electric impulse to the artery wall, proximally to the denervation location, in order to stimulate the nerve and trigger an action potential in the nerves surrounding the artery wall, and measure the magnetic field at the distal location from the denervation position (FIG. 3A), for example using a SQUID magnetometer.

**[0036]** 2. Initiate an electric impulse to the artery wall, distally to the denervation location, in order to stimulate the nerve and trigger an action potential in the nerves surrounding the artery wall, and measure the magnetic field at the proximal location from the denervation position (FIG. 3A), for example using a SQUID magnetometer.

**[0037]** 3. Initiate an electric impulse to the artery wall, proximally to the denervation location, in order to stimulate the nerve and trigger an action potential in the nerves surrounding the artery wall, and measure the current density at the distal location from the denervation position, using ultrasound current source density imaging (UCSDI) measurement method, for example as described in FIG. 2.

**[0038]** 4. Initiate an electric impulse to the artery wall, distally to the denervation location, in order to stimulate the nerve and trigger an action potential in the nerves surrounding the artery wall, and measure the current density at the proximal

location from the denervation position, using ultrasound current source density imaging (UCSDI) measurement method, for example as described in FIG. 2.

**[0039]** 5. Initiate an electric impulse to the renal artery wall, proximally to the denervation location, in order to stimulate the nerve and trigger an action potential in the nerves surrounding the artery wall, and measure a change in absolute and/or relative blood pressure, for example using a pressure transducer that is inserted into the artery.

**[0040]** 6. Initiate an electric impulse to the renal artery wall distally to the denervation location, in order to stimulate the nerve and trigger an action potential in the nerves surrounding the artery wall, and measure a change in absolute and/or relative blood pressure, for example using a pressure transducer that is inserted into the artery.

**[0041]** 7. Initiate an electric impulse to the renal artery wall distally to the denervation location, in order to stimulate the nerve and trigger an action potential in the nerves surrounding the artery wall, and measure the sympathetic neural activity in the brain (FIG. 3B), for example using EEG. Optionally, sympathetic neural activity in the brain is correlated with renal neural activity.

**[0042]** 8. Initiate an electric impulse to the renal artery wall distally to the denervation location, in order to stimulate the nerve and trigger an action potential in the nerves surrounding the artery wall, and measure and/or evaluate any visual and/or physical response which is correlated with neural activation.

**[0043]** The described above, for example in sections 6-8, can be performed in other location such as the aorta and/or any other location in which a nerve and/or a nerve bundle was denervated.

**[0044]** In some embodiments, the electric stimulation may be applied using, for example, an intravascular apparatus comprising electrodes, for example an intravascular balloon with electrodes, a catheter, guide wire, guiding catheter, and/or a therapeutic device, for example with integrated electrodes.

**[0045]** In some embodiments, bio impedance measurements of the artery wall are performed, for example following an externally applied stimulation. Optionally, the measurements reflect a change in artery wall tissue condition and/or neural conductivity.

**[0046]** An Exemplary Method for Denervation Assessment which Includes Recording Evoked Potentials Before and/or after a Denervation Treatment

**[0047]** FIG. 4 describes a method which includes recording evoked potential before and/or after a denervation treatment, according to some embodiments of the invention.

**[0048]** In some embodiments, the method comprises initiating a short duration pulse of thermal modulation 401 with “n” repetitions distally to the denervation location, in order to stimulate the A-Delta and C-Fiber action potential and measure the activity in the brain by using, for example, evoked potentials measured by EEG 405, EMG, and/or fMRI. In some embodiments, an evoked potential detecting software 407 is used for analysis. In some embodiments, a cooling method may be used instead of thermal modulation.

**[0049]** In some embodiments, the thermal modulation is performed using RF energy, and/or ultrasonic energy. Optionally, the RF energy is unipolar and/or bipolar. Optionally, the ultrasonic energy is emitted as a focused beam. Alternatively, ultrasonic energy is emitted as a non-focused beam. Optionally, the ultrasonic energy is emitted from a single element and/or multiple elements, such as an array of elements.

**[0050]** In some embodiments, a TIVUS™ system is used for emitting ultrasonic energy to achieve thermal modulation. Optionally, the TIVUS™ is connected to a standard EEG recorder and/or to software for detecting evoked potentials.

**[0051]** An Exemplary Method for Measuring and/or Evaluating Renal Denervation Based on Optogenetic Controls of Neural Excitability

**[0052]** FIG. 5 relates to a method for measuring and/or evaluating renal denervation based on optogenetic controls of neural excitability, according to the expression of light-activated microbial rhodopsins channelrhodopsin-2 (ChR2)1 from *Chlamydomonas reinhardtii*, a cation-permeable channel that enables cell depolarization (neuronal activation) in response to blue light, and halorhodopsin from *Natromonas pharaonis* (NphR or Halo)2,3, a chloride pump that enables cell hyperpolarization (neuronal silencing) in response to orange light. The ability to drive and block electrical activity at defined locations, for example, at a dendritic spine or a synaptic terminal, may also be beneficial and may require co-localization of ChR2 and NphR.

**[0053]** FIG. 5 shows a design of protein chimeras and functional evaluation of ChR2-EYFP-βbR, ChR2-EYFP-βNphR and hChR2(H134R)-mKate-hβbR. The figure shows a schematic drawing of the ChR2-EYFP-βbR construct after ligation of ChR2-EYFP with βbR. βHK, β helix derived from the H<sup>+</sup>,K<sup>+</sup>-ATPase β subunit; bR, bacteriorhodopsin. Blue and orange arrows indicate light spectrum that preferentially activates each protein.

**[0054]** In some embodiments, the method comprises exposing the renal artery nerves to blue and/or orange light, proximally to the denervation location, in order to stimulate or suppress neural activity, and measure the change in blood pressure following this action. In some embodiments, an optical fiber and/or LED device are used for delivering light to the renal artery.

**[0055]** In some embodiments, the method comprises exposing the renal artery nerves to blue and/or orange light, distally to the denervation location, in order to stimulate or suppress neural activity in nerves surrounding the artery wall, and measure the sympathetic neural activity in the brain.

**[0056]** In some embodiments, the method comprises exposing the renal artery nerves to blue and/or orange light, distally to the denervation location, in order to stimulate or suppress neural activity in nerves surrounding the artery wall, and measure and/or evaluate any visual and/or physical response correlated with neural activation and/or deactivation.

**[0057]** In some embodiments, the method comprises exposing the renal artery nerves to blue and/or orange light, distally to the denervation location, in order to stimulate or suppress neural activity in nerves surrounding the artery wall, and measure absolute and/or relative blood pressure.

**[0058]** An Exemplary General Method for Denervation Treatment and Assessment

**[0059]** FIG. 6 is a flowchart of a general method for denervation treatment and assessment, according to some embodiments of the invention.

**[0060]** In some embodiments, a decision to perform renal denervation treatment is made, for example by a physician (601). In some embodiments, pre-treatment measurements are performed (603), internally and/or externally to the treated artery. Examples for the pre-treatment measurements include measuring the blood flow rate, blood pressure, and/or a diameter of the renal artery. Optionally, measurements are

performed using instruments such as flow wire for example to determine blood flow, a duplex ultrasound device for example to determine a cross section of the artery, and/or a therapeutic device, such as a TIVUS™ device, for example by applying and/or receiving and/or analyzing ultrasonic energy. Optionally, the device is used for performing measurements as well as for applying energy to denervate the nerves.

**[0061]** In some embodiments, a denervation profile is determined (605). Optionally, the profile is determined according to the measured data and/or according to other medical information related to the patient. In some embodiments, determining the denervation profile includes selecting a device for performing the treatment, setting a treatment duration, setting an intensity of the applied energy, etc.

**[0062]** In some embodiments, the treatment is applied at a plurality of locations along the renal artery (607), for example 1 location, 2 locations, 3 locations, 10 locations and/or intermediate or higher numbers of locations. For example, if two locations are selected, one location may be selected adjacent to the main bifurcation, and a second selected at the renal artery ostium. Optionally, the treatment profile is adjusted (609). Optionally, the treatment is repeated for the same renal artery (609), and/or repeated for a second renal artery (611).

**[0063]** In some embodiments, post-treatment measurements are performed (613). Optionally, the post-treatment measurements are performed immediately after the treatment, such as 1 minute, 20 minutes, 1 hour or intermediate time after the treatment. Optionally, the post-treatment measurements are performed at a later time, such as 1 day, 5 days, 30 days, 60 days, 120 days or intermediate or later times after the treatment. Examples for the post-treatment measurements include measuring the blood flow rate, blood pressure, blood flow velocity, and/or a diameter of the renal artery. Optionally, measurements are performed using a flow wire, a duplex ultrasound device, and/or a therapeutic device, such as a TIVUS™ device.

**[0064]** In some embodiments, measurements are performed during the denervation treatment, for example to determine if the treatment profile needs to be adjusted and/or if the treatment duration should be lengthened.

**[0065]** In some embodiments, pre and/or post treatment measurements are performed distally to the denervation site, for example at a distance ranging between 5-10 cm from the denervation location. Additionally and/or alternatively, measurements are performed proximally to the denervation site, for example at a distance ranging between 0.1-5 cm from the denervation location, for example in vertical and/or horizontal directions in the artery.

**[0066]** In some embodiments, the measured data is analyzed (615). Optionally, post-treatment measurements are compared to the pre-treatment measurements. In one example, the renal blood flow rate is analyzed. Optionally, a threshold is determined in order to decide if the treatment should be repeated. For example, if the renal blood flow rate measured post-treatment, for example immediately post treatment, is not at least 100%, 50%, 70%, 150%, and/or higher, smaller or intermediate percentages higher than the blood flow rate measured pre-treatment, the denervation treatment is repeated. Optionally, the blood flow rate changes over time, and a threshold may be predefined accordingly if the blood flow rate measurement is repeated, for example, 2 days, 1 month, months, or any other time after the denervation treatment.

**[0067]** An Exemplary Method for Assessing Denervation Treatment by Tracking Physiological Changes at a Specific Location Along the Artery Over Time

**[0068]** FIG. 7 is a flowchart of a method for assessing denervation treatment by tracking physiological changes at a specific location along the artery over time, according to some embodiments of the invention.

**[0069]** In some embodiments, a measurement device is inserted into a renal artery (701). Optionally, the measurement device is mounted on a catheter tip. In some embodiments, the measurement device comprises an ultrasonic transceiver and/or transducer, for example a TIVUS™ device, which is adapted for applying ultrasonic energy for example to cause tissue ablation to denervate nerves, and/or adapted for receiving ultrasonic energy such as returning echo signals from walls of an artery. In some embodiments, measurements are performed externally to the artery, for example using a duplex ultrasound device. Other examples of measurement devices and/or systems may include a flow wire, a duplex ultrasound catheter, a CT angiography system, an MRI angiography system and/or any other device capable of measuring at least one of the parameters described herein.

**[0070]** In some embodiments, using the measurement device, one or more of the following parameters are tracked over time: arterial wall movement, arterial blood flow rate, arterial blood flow velocity, blood pressure, and/or arterial diameter (703).

**[0071]** In some embodiments, measurements are performed at a specific location along the artery, for example at a nerve denervation location. Optionally, measurements are performed at a non-treated location, for example a location found in some distance from a nerve denervation location, such as 0.1 cm, 2 cm, 5 cm or smaller, intermediate, or larger distances from a denervation location.

**[0072]** In some embodiments, tracking over time comprises measuring the above mentioned parameters before and/or during and/or after a denervation treatment. In one example, blood flow rate and/or blood pressure are measured continuously throughout the treatment procedure, for example tracked for 2-5 hours continuously. In some embodiments, measurements are performed periodically, for example every 1 second, every 30 seconds, every minute, every 5 minutes, every 1 hour, or any other time intervals. Optionally, a measurement is performed only once.

**[0073]** In some embodiments, by analyzing the measurement results, the effectiveness of the denervation treatment is assessed (705). In some embodiments, analyzing comprises comparing measurements taken before and/or during and/or after a denervation treatment, for example changes to arterial diameter may be analyzed to detect a widening or a narrowing of the artery at one or more locations along the artery. In some embodiments, analyzing comprises combining two or more measured parameters, such as the blood flow rate and the arterial diameter at a specific location, to determine the effectiveness of the treatment. Optionally, combining results may point to a possible synergy between two or more parameters. Optionally, combining results may reduce systemic errors.

**[0074]** In some embodiments, analyzing comprises detecting a maximal and/or minimal diameter of the artery, and/or detecting a pattern in arterial wall movement over time.

**[0075]** In some embodiments, arterial wall movement is determined by measuring a distance between an arterial wall and a catheter that is inserted into the renal artery, such as a TIVUS catheter. Optionally, distance is measured using ultra-

sonic imaging. Optionally, an additional element is used in order to affix the measurement device in position during distance measurement, for example to maintain a catheter in the center of the artery with respect to the artery walls.

**[0076]** In some embodiments, arterial wall movement is determined using a two dimensional ultrasonic device, for example externally to the artery. In some embodiments, arterial wall movement and/or arterial diameter are detected and measured by ultrasonic imaging. In some embodiments, arterial wall movement is measured, and the arterial diameter is deduced from the wall movement measurement.

**[0077]** Some embodiments comprise assessing arterial stiffness (707), for example by tracking arterial wall movement over time. Optionally, the differences in amplitudes of the arterial wall movement due to pulsation indicate the capability of the artery to expand. A low expansion ability of the artery may indicate a high level of arterial stiffness, and vice versa.

**[0078]** Some embodiments comprise assessing potential kidney function (709), for example to determine the extent of blood pressure regulation and decide whether sufficient treatment was performed to prevent hypertension. In some embodiments, kidney function assessment is determined according to the level of arterial stiffness. For example, a high level of arterial stiffness may be linked to high blood pressure, whereas blood pressure is at least partially regulated by the kidney.

**[0079]** In some embodiments, the results of the measurements directly indicate a condition of the renal nerves. In some embodiments, the results of the measurements indicate the functioning of the kidney. In some embodiments, blood flow measurements such as blood flow rate and/or velocity measurements are correlated with kidney function.

**[0080]** In some embodiments, a blood pressure regulating medication is given to a patient. Optionally, measurements of physiological changes are performed following an effect induced by the medication.

**[0081]** An Exemplary Detailed Method for Evaluating Mechanical Parameters of the Artery for Assessing Renal Denervation

**[0082]** In some embodiments, the method includes performing baseline measurements, for example before the treatment, such as 1 day, 2 hours, 30 minutes, 5 minutes or any other times before the treatment. Optionally, if the measurement is performed immediately before the treatment, stress experienced by the patient may affect the measurement results. Optionally, two or more baseline measurements are performed, for example one measurement a week before the treatment, and a second measurement immediately before the treatment, to provide a more accurate estimation.

**[0083]** In some embodiments, the measurements include measuring a diameter of the artery, measuring renal blood flow rate, measuring renal blood flow velocity, measuring blood pressure and/or measuring artery wall movement. In some embodiments, measurements are performed from within a lumen of the artery. Additionally and/or alternatively, measurements are performed externally to the artery. Optionally, as shown, for example, in FIG. 8, a flow wire 801 or any other flow measurement device can be inserted into the renal artery, for example via a femoral approach, to measure flow rate and/or velocity. Optionally, the flow wire can be positioned at a distal segment of the main stem of the renal artery 803, for example in proximity to the main bifurcation 805, or at any other location along the artery. Optionally, measure-

ments are performed at one or more locations 807 along the artery (marked by X's). Optionally, an external duplex ultrasound device 901, as shown for example in FIG. 9, can be used, for example, to determine a diameter of the artery. In some embodiments, a TIVUS™ catheter is used for measuring one or more of the parameters described herein, for example comprising ultrasonic transceivers to measure arterial diameter by measuring a distance to an artery wall, according to returning echo signals from the artery walls.

**[0084]** In some embodiments, the method includes inserting a device for performing renal denervation into a renal artery, for example a TIVUS™ catheter, or any other renal denervation system. Optionally, energy such as RF and/or ultrasonic energy is applied to cause tissue ablation and denervate nerves along and/or within the artery, for example nerves surrounding the main stem of the renal artery. In some embodiments, treatment is applied to several selected locations, for example 3, 5, 10 or intermediate, higher, or small number of locations. In some embodiments, ultrasonic energy is applied in one or more directions, such as 1,2,3,4, 5,6 directions, for example circumferentially towards the artery walls. In some embodiments, a duration of treatment at each of the locations ranges, for example, between 10-200 seconds. In some embodiments, various frequencies and intensities may be applied, for example a frequency of 10 MHz and an intensity of 30-40 W/cm<sup>2</sup> may be used.

**[0085]** In some embodiments, the method includes performing post denervation measurements, for example 5 minutes, 20 minutes, 30 minutes, 1 day, 2 days after the treatment. In some embodiments, measurements are performed in the same location that they were performed before the treatment and/or during the treatment. In some embodiments, measurements are performed immediately after the treatment is completed and/or immediately after denervation at each of the locations along the artery. Optionally, a TIVUS catheter is used for performing the measurements. Alternatively, the TIVUS catheter is removed before measuring, for example measuring blood flow rate, so as to not interrupt the blood flow through the artery.

**[0086]** In some embodiments, the pre-denervation measurements and the post-denervation measurement and/or measurements performed during the treatment are compared in order to determine the effectiveness of the renal denervation treatment.

#### Various Embodiments of the Invention

**[0087]** Some embodiments of the invention relate to measuring neural activity, conductivity and/or continuity before and/or during and/or after a denervation treatment, for example to determine the effectiveness of the treatment.

**[0088]** In some embodiments, measurements are conducted in real time and/or for example immediately after the procedure, optionally reducing and/or eliminating the need for chemical based measurements which may reflect denervation after a relatively long period of time, such as days or months, depending on the chemical marker that was used.

**[0089]** Some embodiments of the invention relate to measuring renal neural activity. Some embodiments comprise estimating neural activity in other organs of the body using the methods described herein. Optionally, various physiological responses are determined using the methods described herein.

**[0090]** Some embodiments of the methods and/or apparatuses may include a standalone and/or integrated system comprising:

**[0091]** a console that controls parts of the system used for applying treatment and/or for measuring and/or for initiating stimulation. Optionally, the console performs analysis and/or contains a user interface and/or displays measurements and/or communicates with additional devices and/or initiates triggering, such as neural stimulation.

**[0092]** one or more parts for applying measurements and/or initiating triggering and/or treating, such as electrodes, transceivers, and/or transducers.

**[0093]** an integrated device and/or software that is a part of an existing or commonly used measurement and/or imaging systems and/or triggering systems.

**[0094]** Some embodiments of the methods and/or apparatuses of the components used for applying treatment and/or for stimulating and/or for measuring may be mounted on and/or assembled to:

**[0095]** a guide wire

**[0096]** a guiding catheter

**[0097]** a standalone catheter with a sensing head and/or body

**[0098]** one or more sensors that are integrated onto an existing device

**[0099]** The described methods can be performed, for example, prior to and/or post denervation treatments in order to compare relative neural activity prior to and post denervation; and to detect an absolute value of neural activity which may reflect neural conductivity and/or continuity.

**[0100]** Some embodiments include implementing a signal processing analysis, for example to achieve a higher signal to noise ratio and/or reflect trends and/or special phenomenon. The analysis may include, for example, a smoothing algorithm, FFT, a pattern matching algorithms, etc. For example, FFT may be applied to returning echo signals received by ultrasonic transceivers, for example of the TIVUS device, to determine, for example, wall movement as a function of time. In another example, FFT may be applied to EEG signals that are recorded in the brain during stimulation of the renal artery nerves.

**[0101]** In some embodiments, methods for verifying and/or validation renal denervation treatment are based on the following:

**[0102]** Sympathetic neural control affects not only small resistance arteries but also the mechanical properties of large arteries. For example, pharmacological or electrical activation of the sympathetic nervous system has been shown to reduce distensibility of small and medium-size arteries in animals. Furthermore, maneuvers that increase sympathetic stimulation have been associated with a reduction of radial artery distensibility in humans. Furthermore, there is evidence that in animals, small-artery distensibility is increased by the removal of sympathetic influences and that in humans, radial artery distensibility increases after transient anesthesia of the brachial plexus. This suggests that the sympathetic nervous system may increase arterial wall stiffness not only physically but also tonically. In addition, there is growing evidence that both sympathetic over activity and arterial stiffening are implicated in the development of hypertension and its complications. Sympathetic activity may contribute to myocardial hypertrophy and vascular remodeling. Experimental studies suggest that sympathetic neural mechanisms

may have a stiffening influence on arterial mechanical properties. In rats, sympathectomy and a receptor blockade increase distensibility of both carotid and femoral arteries. These suggest that sympathetic vasoconstrictor mechanisms modulate arterial elastic properties. Indeed, in humans, removal of adrenergic tone by anesthesia of the brachial plexus and the spinal cord results in marked increased distensibility of radial artery and femoral artery, respectively.

**[0103]** Optionally, based on the above, some embodiments include the following methods and/or combinations of them, for example to determine the effectiveness of a renal denervation treatment.

**[0104]** Some embodiments comprise measuring renal artery stiffness using ultrasonic imaging techniques.

**[0105]** Some embodiments comprise measuring renal artery wall movement using ultrasonic echo measurement from artery wall.

**[0106]** Some embodiments comprise measuring renal artery wall movement's amplitude in a given duration using ultrasonic echo measurement from artery wall. Optionally, the amplitude is measured with respect, but not limited to, blood pressure and/or pulsation.

**[0107]** Some embodiments comprise measuring a diameter of the renal artery using ultrasonic imaging techniques. Optionally, the diameter is measured with respect, but not limited to, blood pressure and/or pulsation.

**[0108]** Some embodiments comprise measuring renal artery stiffness using Pulse Wave Velocity measurement method, for example by using pressures sensors distally and/or proximally to the denervation location inside the renal artery.

**[0109]** Some embodiments comprise measuring absolute blood flow and/or a change in blood flow prior to and/or post denervation. Optionally, a change in blood flow rate reflects neural activity level and/or a condition of the nerves. In some embodiments, the blood flow measurement can be combined with one or more of the following: initiation of an electric impulse to the artery wall, proximally to the denervation location, and/or an injection of a drug to the kidney, to regulate blood pressure.

**[0110]** In some embodiments, any of the above parameters such as blood flow rate, artery diameter, and/or artery wall movement are measured before and/or after the denervation procedure. In some embodiments, the measured values are compared. Optionally, the measured values are analyzed using a signal processing method.

**[0111]** In some embodiments, any of the above parameters are compared to previously known values, for example pre-research values.

**[0112]** In some embodiments, a formula and/or table is used for analyzing the measured data.

**[0113]** Following is a list of methods/and or features and/or devices and/or systems relating to the assessment of renal denervation effectiveness, according to some embodiments of the invention:

**[0114]** A. Some embodiments relate to a medical measurement device for sensing the neural activity comprising at least one magnetometer that is positioned inside a vessel.

**[0115]** B. Some embodiments relate to a device, for example a device according to section A, wherein the magnetometer is a SQUID magnetometer.

**[0116]** C. Some embodiments relate to a device, for example a device according to section B, wherein the SQUID magnetometer comprises at least one coil.

**[0117]** D. Some embodiments relate to a medical measurement device for imaging neural activity, which comprises at least one of the following:

**[0118]** High spatial resolution ultrasonic imaging

**[0119]** Ultrasound current source density imaging (UCSDI)

**[0120]** Acoustoelectric (AE) modulated voltage recordings to map and reconstruct current densities

**[0121]** E. Some embodiments relate to a medical measurement device for sensing neural activity, which comprises at least one bio impedance measurement sensor.

**[0122]** F. Some embodiments relate to a medical measurement system for measuring at least one mechanical parameter of a blood vessel together with at least one of the following manipulations, in order to estimate renal denervation:

**[0123]** Electric impulse to the artery wall, proximally to the denervation location

**[0124]** Injection of a drug to the kidney to regulate blood pressure

**[0125]** G. Some embodiments relate to a system, for example a system according to section F, wherein the system controls and synchronizes the manipulations and measuring techniques.

**[0126]** H. Some embodiments relate to a device, for example a device according to section A and section D, wherein the device is included in a system which further comprises at least one of the following:

**[0127]** A stimulator to the artery wall that stimulates the nerves

**[0128]** Means for synchronizing between the stimulator and the measurement device

**[0129]** I. Some embodiments relate to a system, for example the system according to section H, wherein the stimulator is an electric impulse stimulator.

**[0130]** J. Some embodiments relate to a system, for example the system according to sections H, and I, wherein synchronization is based on stimulating nerves distally to the treated location, and measuring proximally to the treated location.

**[0131]** K. Some embodiments relate to a system, for example the system according to sections H, and I, wherein synchronization is based on stimulating nerves proximally to the treated location and measuring distally to the treated location.

**[0132]** L. Some embodiments relate to a system, for example the system according to section F, wherein the mechanical parameter is blood flow.

**[0133]** M. Some embodiments relate to a system, for example the system according to section F, wherein the mechanical parameter is blood pressure.

**[0134]** N. Some embodiments relate to a device that electrically stimulates the artery wall by causing evoked potential in the nerves surrounding the artery.

**[0135]** O. Some embodiments relate to a device, for example a device according to section N, wherein the device is included in a system that further comprises at least one of the following features:

**[0136]** Measuring the sympathetic activity in the brain

**[0137]** Measuring and/or evaluating any visual and/or physical responses which are correlated with neural activation.

**[0138]** Measuring EEG in a specific location

**[0139]** Measuring fMRI

- [0140] Synchronizing between the stimulator and the measurement device
- [0141] P. Some embodiments relate to a device that thermally heats the artery wall for causing evoked potential in C-fibers and A-delta nerves surrounding the artery.
- [0142] Q. Some embodiments relate to a device, for example a device according to section P, which is combined in a system comprising at least one of the following:
- [0143] Measuring the sympathetic activity in the brain
  - [0144] Measuring and/or evaluating any visual and/or physical responses which are correlated with neural activation.
  - [0145] Measuring EEG in a specific location
  - [0146] Measuring fMRI
  - [0147] Synchronizing between the stimulator and the measurement device
- [0148] R. Some embodiments relate to a device that stimulates the nerves surrounding the artery by exposing the nerve to at least one of the following:
- [0149] Blue light
  - [0150] Orange light
- [0151] S. Some embodiments relate to a device, for example the device according to section R, wherein the device is included in a system which further comprises at least one of the following features:
- [0152] Measuring the sympathetic activity in the brain
  - [0153] Measuring and/or evaluating any visual and/or physical responses which are correlated with neural activation.
  - [0154] Measuring EEG in a specific location
  - [0155] Measuring fMRI
- [0156] T. Some embodiments relate to a device, for example the device according to section N, wherein the electric stimulator is at least one of the following:
- [0157] Intravascular Balloon with electrodes
  - [0158] Intravascular apparatus includes electrodes
  - [0159] Catheter and/or guide wire and/or guiding catheter and/or a therapeutic device with integrated electrodes.
- [0160] U. Some embodiments relate to a medical measurement device for evaluating renal denervation comprising at least of the following features:
- [0161] Measuring renal artery stiffness using ultrasonic imaging techniques
  - [0162] Measuring renal artery wall movement using ultrasonic echo measurement from artery wall
  - [0163] Measuring renal artery wall movement amplitude in a given duration using ultrasonic echo for measuring the distance between the sensing element and the artery wall, with respect, but not limited, to blood pressure
  - [0164] Measuring renal artery diameter using ultrasonic imaging techniques, with respect, but not limited, to blood pressure
  - [0165] Measuring renal artery stiffness using Pulse Wave Velocity (PWV) measurement method, by using pressure sensors distally and/or proximally to denervation location inside the renal artery.
- [0166] V. Some embodiments relate to a device, for example according to any of the sections herein, wherein the imaging is performed distally to the denervation location.
- [0167] W. Some embodiments relate to a device, for example according to any of the sections herein, wherein the imaging is performed proximally to the denervation location.
- [0168] X. Some embodiments relate to a device, for example according to any of the sections herein, wherein imaging and/or measuring is performed prior to the renal denervation procedure.
- [0169] Y. Some embodiments relate to a device, for example according to any of the sections herein, wherein imaging and/or measuring is performed after a renal denervation procedure.
- [0170] Z. Some embodiments relate to a device, for example according to any of the sections herein, wherein imaging and/or measurement results are compared to pre-research results.
- [0171] Aa. Some embodiments relate to a device, for example according to any of the sections herein, wherein imaging and/or measurement results are compared to a table and/or formula that evaluates denervation rate.
- [0172] Bb. Some embodiments relate to a device, for example according to any of the sections herein, wherein the sensing and/or measuring method is actuated and/or applied by and/or combined to one of the following:
- [0173] An intravascular Balloon
  - [0174] An intravascular apparatus
  - [0175] A catheter
  - [0176] A guide wire
  - [0177] A therapeutic device
  - [0178] A sheath
- [0179] In some embodiments, devices and/or systems and/or methods and/or components as described in one or more of the following applications may be used for measuring renal denervation effectiveness using methods described herein:
- [0180] PCT/IB2011/054634 filed on Oct. 18, 2011, entitled "THERAPEUTICS RESERVOIR" (Attorney Docket No. 52341), relating to a method of drug delivery and, more particularly, to a method for trapping drugs to form a drug reservoir in tissue;
- [0181] PCT/IB2011/054635 filed on Oct. 18, 2011, entitled "ULTRASOUND EMISSION ELEMENT" (Attorney Docket No. 52344), showing, for example, an apparatus for generating relatively high efficiency ultrasound;
- [0182] PCT/IB2011/054636 filed on Oct. 18, 2011, entitled "AN ULTRASOUND TRANSCIEVER AND USES THEREOF" (Attorney Docket No. 52345), showing for example, a method for feedback and control of the ultrasonic transducer;
- [0183] PCT/IB2011/054641 filed on Oct. 18, 2011, entitled "AN ULTRASOUND TRANSCIEVER AND COOLING THEREOF" (Attorney Docket No. 52346), showing for example, a method for blood flow cooling of the ultrasonic transducer;
- [0184] PCT/IB2011/054640 filed on Oct. 18, 2011, entitled "TISSUE TREATMENT" (Attorney Docket No. 52347), showing for example, a method of selective targeting and treating tissues using ultrasound;
- [0185] PCT/IB2011/054638 filed on Oct. 18, 2011, entitled "SEPARATION DEVICE FOR ULTRASOUND ELEMENT" (Attorney Docket No. 52348), showing for example, a device to prevent the transducer from touching the blood vessel wall; and
- [0186] PCT/IB2011/054639 filed on Oct. 18, 2011, entitled "AN ULTRASOUND TRANSCIEVER AND CONTROL OF A THERMAL DAMAGE PROCESS" (Attorney Docket No. 52342), showing for example, an ultrasound transceiver and to control of an ablation or thermal damage process to a tissue.

**[0187]** The terms “comprises”, “comprising”, “includes”, “including”, “having” and their conjugates mean “including but not limited to”.

**[0188]** The term “consisting of” means “including and limited to”.

**[0189]** The term “consisting essentially of” means that the composition, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.

**[0190]** As used herein, the singular form “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a compound” or “at least one compound” may include a plurality of compounds, including mixtures thereof.

**[0191]** Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

**[0192]** Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases “ranging/ranges between” a first indicate number and a second indicate number and “ranging/ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.

**[0193]** As used herein the term “method” refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.

**[0194]** As used herein, the term “treating” includes abrogating, substantially inhibiting, slowing or reversing the progression of a condition, substantially ameliorating clinical or aesthetical symptoms of a condition or substantially preventing the appearance of clinical or aesthetical symptoms of a condition.

**[0195]** It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.

**[0196]** Although the invention has been described in conjunction with specific embodiments thereof, it is evident that

many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.

**[0197]** All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting.

**[0198]** The following is a list of references which may be relevant to the methods and/or apparatuses and/or features disclosed herein:

#### REFERENCES

- [0199]** [1] Magnetic Field of a Nerve Impulse: First Measurements
- [0200]** John P. Wikswo, John P. Barach, John A. Freeman
- [0201]** Science, Vol 208 (4439), pp 53-55, 1980
- [0202]** [2] A gene-fusion strategy for stoichiometric and co-localized expression of light-gated membrane proteins
- [0203]** Sonja Kleinlogel<sup>1</sup>, Ulrich Terpitz<sup>1,4</sup>, Barbara Legrum<sup>1</sup>, Deniz Gökbuğut<sup>1,4</sup>, Edward S Boyden<sup>2</sup>, Christian Bamann<sup>1</sup>, Phillip G Wood<sup>1</sup> & Ernst Bamberg<sup>1,3</sup>
- [0204]** [3] Ultrasound Current Source Density Imaging
- [0205]** Ragnar Olafsson, Student Member, IEEE, Russell S. Witte, Member, IEEE, Sheng-Wen Huang, Member, IEEE, and Matthew O'Donnell, Fellow, IEEE
- [0206]** [4] Effect of Sympathectomy on Mechanical Properties of Common Carotid and Femoral
- [0207]** Arteries
- [0208]** Arduino A. Mangoni; Luca Mircoli; Cristina Giannattasio; Giuseppe Mancina; Alberto U. Ferrari
- [0209]** [5] An independent relationship between muscle sympathetic nerve activity and pulse wave velocity in normal humans
- [0210]** Ewa S'wierblewskaa, Dagmara Hering a, Tomas Karab, Katarzyna Kunicka, Piotr Kruszewskia, Leszek Bieniaszewska, Pierre Boutouyric, Virend K. Somersb and Krzysztof Narkiewiczza,b
- What is claimed is:
1. A method for assessing renal denervation treatment, comprising
    - inserting a measurement device into an artery;
    - tracking at least one of arterial wall movement, arterial blood flow rate, arterial blood flow velocity, blood pressure and arterial diameter at one or more selected locations in the renal artery over time; and
    - assessing the effectiveness of said renal denervation treatment according to results obtained by said tracking.
  2. The method according to claim 1, wherein said selected location is a location of tissue ablation.
  3. The method according to claim 1, wherein said selected location is at a horizontal distance of at least 0.5 cm from a location of tissue ablation.
  4. The method according to claim 1, wherein said tracking over time comprises measuring at least one of said parameters continuously during said denervation treatment.

5. The method according to claim 1, wherein said tracking over time comprises measuring at least one of said parameters at least 5 times, periodically every 30 seconds.

6. The method according to claim 1, wherein said assessing is performed by analyzing measurement results of two or more parameters combined together.

7. The method according to claim 1, wherein assessing comprises detecting a change in arterial diameter over time.

8. The method according to claim 1, wherein a stiffness of said artery is determined according to at least one of arterial wall movement profile measured over time, and pulse wave velocity.

9. The method according to claim 1, wherein said effectiveness is assessed by comparing pre-denervation and post-denervation measurements.

10. The method according to claim 1, wherein a single measurement device adapted for emitting and receiving ultrasonic energy is used for treating and for measuring.

11. The method according to claim 1, wherein said measurement device is positioned externally to the renal artery.

12. The method according to claim 1, wherein a denervation treatment profile is adjusted according to results of said tracking of at least one parameter.

13. The method according to claim 12, wherein assessing comprises determining if the denervation treatment should be repeated by applying a threshold to said at least one tracked parameter.

14. The method according to claim 12, wherein said adjusting said denervation treatment profile comprises selecting at least one of a treatment duration, a treatment location, and an intensity of the applied energy for denervating the nerves.

15. A device comprising a plurality of ultrasonic transceivers for determining effectiveness of a renal denervation treatment, said device adapted to measure renal artery stiffness.

16. The device according to claim 15, wherein said device is adapted to measure renal artery wall movement using echo signals reflected by the artery wall.

17. The device according to claim 16, further adapted to calculate an amplitude of the artery wall movement by measuring a distance between at least one of said transceivers and the artery wall.

18. The device according to claim 15, wherein said device is adapted to measure a diameter of the renal artery using ultrasonic imaging.

19. The device according to claim 15, wherein said device is adapted to measure renal artery stiffness by calculating pulse wave velocity.

\* \* \* \* \*

专利名称(译)	用于测量肾去神经支配效果的方法和/或设备		
公开(公告)号	<a href="#">US20140012133A1</a>	公开(公告)日	2014-01-09
申请号	US13/905224	申请日	2013-05-30
申请(专利权)人(译)	CARDIOSONIC LTD.		
当前申请(专利权)人(译)	CARDIOSONIC LTD.		
[标]发明人	SVERDLIK ARIEL DILMONEY BENNY ZADOK YEHUDA SHABTAY OR		
发明人	SVERDLIK, ARIEL DILMONEY, BENNY ZADOK, YEHUDA SHABTAY, OR		
IPC分类号	A61B5/00 A61B5/026 A61B5/107 A61B5/0205 A61B5/04 A61N7/02 A61B8/12 A61B8/06 A61B5/0476 A61B5/02 A61B8/04		
CPC分类号	A61B5/4848 A61B5/02007 A61B5/026 A61B5/1076 A61B5/0205 A61B5/4836 A61B8/04 A61N7/022 A61B8/12 A61B8/06 A61B5/0476 A61B5/04005 A61B8/0891 A61B8/485 A61N2007/003 A61N2007 /0052 A61B5/0036		
优先权	61/653515 2012-05-31 US		
外部链接	<a href="#">Espacenet</a> <a href="#">USPTO</a>		

摘要(译)

在本发明的一些实施方案中，本发明涉及用于测量肾去神经支配治疗的有效性的方法和/或装置。在一些实施方案中，用于确定去神经支配治疗的有效性的方法包括跟踪肾动脉中一个或多个选定位置处的动脉壁运动，动脉血流速率，动脉血流速度，血压和动脉直径中的至少一个随时间的变化。根据跟踪获得的结果评估所述肾去神经支配治疗的有效性。

